| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A472 | Atinumab (NG-101) Featured |
|
|
| A473 | LK-1 Featured |
|
|
| A474 | CDX-0158 Featured |
|
|
| A475 | LOP628 Featured |
|
|
| A476 | Wuhan U. patent anti-Nav1.9 Featured |
|
|
| A477 | Duke anti-NAv1.7 Featured |
|
|
| A478 | Pepinemab Featured | Pepinemab (VX 15/2503) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), also known as CD100, which is a regulator of neuronal development and plays a role in a variety of cellular processes. Pepinemab can be used in the study of various neurodegenerative diseases such as Alzheimer's disease by blocking the activity of SEMA4D. |
|
| A479 | Sanofi patent anti-PAI-1 Featured |
|
|
| A480 | Abbv-011 Featured |
|
|
| A481 | Pritoxaximab Featured | Pritoxaximab is an IgG1κ antibody targeting shiga toxin type 1. |
|
| A482 | Setoxaximab Featured | Setoxaximab is an IgG1-κ humanized chimeric antibody targeting shiga toxin type 1. |
|
| A483 | MVT-5873 Featured |
|
|
| A484 | AB-25E9 Featured |
|
|
| A485 | NC-318 (5G-12) Featured |
|
|
| A486 | Medimmune patent anti-Siglec-15 Featured |
|
|
| A487 | Epratuzumab Featured | Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases. |
|
| A488 | Pinatuzumab Featured | Pinatuzumab is a CD22 monoclonal antibody. Pinatuzumab targets the cell-surface antigen CD22. Pinatuzumab can be used for synthesis of antibody agent conjugates (ADCs) to research several diseases including non-Hodgkin lymphoma (NHL). |
|
| A489 | Inotuzumab-CLM Featured |
|
|
| A490 | Anti-Siglec-2/CD22 Antibody (NCI m971) Featured |
|
|
| A491 | Anti-Siglec-2/CD22 Antibody (NCI m972) Featured |
|
|
| A492 | IMGN779 Featured |
|
|
| A493 | Vadastuximab Featured | Vadastuximab is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine. |
|
| A494 | Gemtuzumab Featured | Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. |
|
| A495 | Refanezumab Featured | Refanezumab (GSK249320) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier (BBB) in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke. |
|
| A496 | Lirentelimab Featured | Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis. |
|
| A497 | BI 765063 Featured |
|
|
| A498 | Hospital for Sick Children patent anti-SIRPA Featured |
|
|
| A499 | KWAR 23 Featured | KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research. |
|
| A500 | SGN-CD352A Featured |
|
|
| A501 | Azintuxizumab Featured | Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin. |
|
